Patent classifications
C07C217/52
Substituted bicyclic compounds
Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Substituted bicyclic compounds
Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Dimethoxyphenylalkylamine activators of serotonin receptors
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder. ##STR00001##
COMPOUNDS FOR MODULATING MITOCHONDRIAL FUNCTION
Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein:
##STR00001##
wherein X is absent, CH.sub.2, or C(O); R.sup.1 is H, OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino; R.sup.2 is H or C.sub.1-6 alkyl; R.sup.3 is H, C.sub.1-6 alkyl, C(O)(C.sub.1-3 alkyl), or C(O)O(C.sub.1-3 alkyl); R.sup.4 is C.sub.3-10 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R.sup.5 groups; and R.sup.5 is OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino.
COMPOUNDS FOR MODULATING MITOCHONDRIAL FUNCTION
Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein:
##STR00001##
wherein X is absent, CH.sub.2, or C(O); R.sup.1 is H, OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino; R.sup.2 is H or C.sub.1-6 alkyl; R.sup.3 is H, C.sub.1-6 alkyl, C(O)(C.sub.1-3 alkyl), or C(O)O(C.sub.1-3 alkyl); R.sup.4 is C.sub.3-10 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R.sup.5 groups; and R.sup.5 is OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino.
DIFLUORINATED COMPOUNDS AS DEPIGMENTING OR LIGHTENING AGENTS
The present invention relates to a compound having the following formula (I) as well as a method for preparing such a compound, a cosmetic or pharmaceutical composition containing such a compound, and the use thereof as a depigmenting, lightening, bleaching or whitening agent and for treating pigmentation disorders, notably by topical application on the skin.
##STR00001##
DIFLUORINATED COMPOUNDS AS DEPIGMENTING OR LIGHTENING AGENTS
The present invention relates to a compound having the following formula (I) as well as a method for preparing such a compound, a cosmetic or pharmaceutical composition containing such a compound, and the use thereof as a depigmenting, lightening, bleaching or whitening agent and for treating pigmentation disorders, notably by topical application on the skin.
##STR00001##
BICYCLIC ANALGESIC COMPOUNDS
Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound described herein.
BICYCLIC ANALGESIC COMPOUNDS
Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound described herein.
Compounds for modulating mitochondrial function
Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein: ##STR00001##
wherein X is absent, CH.sub.2, or C(O); R.sup.1 is H, OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino; R.sup.2 is H or C.sub.1-6 alkyl; R.sup.3 is H, C.sub.1-6 alkyl, C(O)(C.sub.1-3 alkyl), or C(O)O(C.sub.1-3 alkyl); R.sup.4 is C.sub.3-10 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R.sup.5 groups; and R.sup.5 is OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino.